Patents Assigned to Techlab, Inc.
  • Method For Diagnosing Irritable Bowel Syndrome and Monitoring Inflammatory Bowel Disease
    Publication number: 20090253155
    Abstract: A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
    Type: Application
    Filed: June 17, 2009
    Publication date: October 8, 2009
    Applicant: TECHLAB, INC.
    Inventors: JAMES HUNTER BOONE, DAVID MAXWELL LYERLY, TRACY DALE WILKINS, RICHARD LITTLETON GUERRANT
  • Method for monitoring gastrointestinal inflammation in persons with inflammatory bowel disease(IBD)
    Patent number: 7560240
    Abstract: A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: July 14, 2009
    Assignee: TechLab, Inc.
    Inventors: James Hunter Boone, David Maxwell Lyerly, Tracy Dale Wilkins, Richard Littleton Guerrant
  • Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker
    Patent number: 7192724
    Abstract: A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: March 20, 2007
    Assignee: Techlab, Inc.
    Inventors: James Hunter Boone, David Maxwell Lyerly, Tracy Dale Wilkins, Richard Littleton Guerrant
  • Methods to produce high levels of C. difficile toxins
    Patent number: 6939548
    Abstract: The present invention relates to the field of medical immunology and further to pharmaceutical compositions, methods of making and methods of use of vaccines. More specifically this invention relates to recombinant proteins derived from the genes encoding Clostridium difficile toxin A and toxin B, and their use in an active vaccine against C. difficile.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: September 6, 2005
    Assignee: Techlab, Inc.
    Inventors: Tracy D. Wilkins, David M. Lyerly, J. Scott Moncrief, Limin Zheng, Carol Phelps
  • Method and apparatus for distinguishing Crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to Saccharomyces cerevisiae
    Patent number: 6872540
    Abstract: A method and apparatus for the differentiation of Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome, using the presence of fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as a marker for Crohn's disease are provided. The apparatus includes an enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobins for the measurement of total endogenous ASCA in a human fecal sample. The method and apparatus may be used by healthcare providers to distinguish Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: March 29, 2005
    Assignee: Techlab, Inc.
    Inventors: James Hunter Boone, David Maxwell Lyerly, Tracy Dale Wilkins
  • Recombinant toxin A/toxin B vaccine against Clostridium difficile
    Patent number: 6733760
    Abstract: The present invention relates to the field of medical immunology and further to pharmaceutical compositions, methods of making and methods of use of vaccines. More specifically this invention relates to recombinant proteins derived from the genes encoding Clostridium difficile toxin A and toxin B, and their use in an active vaccine against C. difficile.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: May 11, 2004
    Assignee: Techlab, Inc.
    Inventors: Tracy D. Wilkins, David M. Lyerly, J. Scott Moncrief, Limin Zheng, Carol Phelps
  • Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker
    Publication number: 20040033537
    Abstract: A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.
    Type: Application
    Filed: July 30, 2003
    Publication date: February 19, 2004
    Applicant: TECHLAB, INC.
    Inventors: James Hunter Boone, David Maxwell Lyerly, Tracy Dale Wilkins, Richard Littleton Guerrant